Core Insights - The biopharmaceutical industry is characterized by long R&D cycles, high capital investment, and significant risk, making cash flow essential for sustaining operations and innovation [1][2] - The Hong Kong stock market has seen a surge in innovative drug companies going public, with 21 companies listed this year, and notable first-day performances [1] - The STAR Market in China has also opened new financing channels for innovative drug companies, with several firms successfully passing the listing process [2] Group 1: Market Trends - The trend of innovative drug companies going public in Hong Kong is referred to as the "listing wave," with companies like Yinnuo Pharmaceutical seeing first-day gains of up to 206% [1] - The reintroduction of the fifth set of listing standards on the STAR Market has facilitated the listing of companies like Heyuan Biotechnology and Beixin Life [2] Group 2: Company-Specific Insights - Wangshan Wangshui, established in 2013, focuses on small molecule drugs in the fields of neuropsychiatry and reproductive health, but faces challenges in market competition and R&D progress [5] - Financial data indicates significant operational pressure for Wangshan Wangshui, with revenue dropping from 200 million to 11.83 million in 2023-2024, a decline of over 94% [6] - The decline in revenue is primarily attributed to a sharp decrease in licensing income, particularly from the collaboration with Junshi Biosciences on the COVID-19 drug VV116 [7] Group 3: R&D and Product Pipeline - Wangshan Wangshui is attempting to expand the commercial value of VV116 by exploring new indications, such as treatment for respiratory syncytial virus (RSV) [8] - The company has two other core products targeting depression and erectile dysfunction, but both face intense market competition [8] - The company’s financial resources are under pressure due to high R&D expenditures and limited revenue from existing products, necessitating successful fundraising through its IPO [9] Group 4: Competitive Landscape - In contrast to Wangshan Wangshui, Yingen Biotechnology, founded in 2019, specializes in antibody-drug conjugates (ADCs) and has developed a pipeline of 13 candidate drugs [11] - Yingen Biotechnology has accelerated its cash flow through licensing agreements with major companies, resulting in a revenue increase of 22.91% year-on-year [12] - Despite revenue growth, Yingen Biotechnology has experienced a significant increase in net losses, highlighting the challenges of balancing R&D investment with financial performance [12] Group 5: Future Outlook - Analysts emphasize the importance of diversified financing strategies for innovative drug companies to build a "safety net" for R&D [2] - The ability of companies like Yingen Biotechnology to leverage their ADC innovations and partnerships will be crucial for their long-term success and market validation [13]

证券代码：688180 证券简称：君实生物 公告编号：临2025-063 上海君实生物医药科技股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 投资者可于2025年10月22日（星期三）至2025年10月28日（星期二）16:00前登录上证路演中心网站 首页点击"提问预征集"栏目或通过上海君实生物医药科技股份有限公司（以下简称"公司"）邮箱 info@junshipharma.com进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 公司将于2025年10月29日在上海证券交易所网站（www.sse.com.cn）披露公司2025年第三季度报告，为 便于广大投资者更全面深入地了解公司2025年第三季度的经营成果、财务状况，公司计划于2025年10月 29日11：00-12：00召开2025年第三季度业绩说明会，就投资者关心的问题进行交流。 登录新浪财经APP 搜索【信披】查看更多考评等级 （一）投资者可在2025年10月29日（星期三）上午 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於召開2025年第三季度業績說明會的公告》， 僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年10月21日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 证券代码：688180 证券简称：君实生物 公告 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-063 上海君实生物医药科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 29 日（星期三）11：00-12：00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 22 日（星期三）至 2025 年 10 月 28 日（星期 二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海君 实生物医药科技股份有限公司（以下简称"公司"）邮箱 info@junshipharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 公司将于 2025 年 10 月 29 日在上海证券交易所网站（www.sse.com.cn）披 露公司 2 ...

Group 1 - The core point of the news is that Junshi Biosciences experienced a slight decline in stock price and significant trading activity, with notable financing and margin trading figures indicating high levels of investor engagement [1][2][3] Group 2 - On October 20, Junshi Biosciences' stock fell by 0.34%, with a trading volume of 351 million yuan. The financing buy-in amount was 28.92 million yuan, while the financing repayment was 33.51 million yuan, resulting in a net financing outflow of 4.59 million yuan [1] - As of October 20, the total financing and margin trading balance for Junshi Biosciences was 1.401 billion yuan, with the financing balance at 1.39 billion yuan, accounting for 4.69% of the circulating market value, which is above the 90th percentile of the past year [1] - In terms of margin trading, on October 20, Junshi Biosciences had 3,815 shares repaid and 2,550 shares sold short, with a short selling amount of 98,600 yuan. The remaining short selling volume was 284,500 shares, with a margin balance of 11 million yuan, also above the 90th percentile of the past year [1] Group 3 - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs. The main revenue sources are 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [2] - As of June 30, 2025, Junshi Biosciences reported a revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a year-on-year increase of 36.01% [2] Group 4 - As of June 30, 2025, among the top ten circulating shareholders of Junshi Biosciences, the Huaxia SSE STAR 50 ETF held 29.7167 million shares, a decrease of 536,700 shares from the previous period. The E Fund SSE STAR 50 ETF increased its holdings by 630,000 shares to 22.2132 million shares [3] - Hong Kong Central Clearing Limited was the tenth largest circulating shareholder, holding 13.1291 million shares, a decrease of 186,650 shares from the previous period [3]

Core Insights - Shanghai has issued measures to accelerate the innovation of frontier technologies and the cultivation of future industries, aiming to establish a systematic and forward-looking policy framework for the next decade [1] Group 1: Future Industry Development - By 2027, Shanghai aims to break through several disruptive technologies and establish future industry clusters, nurturing around 20 leading enterprises in future industry ecosystems [1] - The city plans to cultivate a number of strategic emerging industries by 2030, positioning itself as a globally influential leader in future industries [1] Group 2: Focus Areas and Initiatives - Shanghai is focusing on six key areas: future manufacturing, future information, future materials, future energy, future space, and future health, with a structured approach to planning and nurturing these sectors [2] - The city has launched multiple cultivation plans in areas such as brain-computer interfaces, quantum computing, silicon photonics, and 6G, and is establishing various proof-of-concept platforms [3] Group 3: Investment and Funding - A future industry fund with a total scale of approximately 15 billion yuan has been established to focus on disruptive innovation and interdisciplinary collaboration in future industries [3] - The fund will adopt a model of "direct investment + sub-fund investment" to create an investment incubation ecosystem that aligns with cutting-edge technological innovations [3] Group 4: Industry Clusters and Support - Shanghai is creating several future industry clusters in locations such as Pudong (silicon photonics), Minhang (brain-computer interfaces), and Yangpu (brain-like intelligence), with plans to establish national-level pilot zones for future industries [5][6] - The city is providing financial support of up to 20 million yuan for qualifying future industry cluster projects to promote high-quality development [5] Group 5: Community and Ecosystem Development - The "Shanghai Future Point Community" is being developed to serve as a hub for top talent and innovation resources, focusing on disruptive innovation and the cultivation of a supportive ecosystem [7] - The community aims to integrate talent, cognition, connection, and paradigms to reshape the foundational models of disruptive innovation [7] Group 6: Strategic Goals - By 2030, Shanghai aims to form several world-leading future industry clusters, leveraging open perspectives and pragmatic measures to implement the outlined initiatives [8]

Core Insights - Shanghai has issued measures to accelerate the innovation of frontier technologies and the cultivation of future industries, aiming to establish a systematic and forward-looking policy framework for the next decade [1] - The goal is to break through several disruptive technologies by 2027 and cultivate around 20 leading enterprises in future industry ecosystems by 2030, positioning Shanghai as a globally influential hub for future industries [1] Group 1: Future Industry Development - Shanghai is focusing on six key areas: future manufacturing, future information, future materials, future energy, future space, and future health, with a structured approach to planning and nurturing these sectors [2] - The city has launched multiple cultivation plans for future industries, including brain-computer interfaces, quantum computing, silicon photonics, and 6G, and is establishing various proof-of-concept platforms [3][4] - A future industry fund with a total scale of approximately 15 billion yuan is being established to support early-stage investments in disruptive innovations across various fields [3] Group 2: Industry Clusters and Innovation Centers - Shanghai is creating several future industry clusters in locations such as Pudong (silicon photonics), Minhang (brain-computer interfaces), and Yangpu (brain-like intelligence), with plans for a national-level future industry pilot zone [5] - The clusters aim to enhance industry integration and resource utilization, providing support of up to 20 million yuan for qualifying construction entities [5] - The Zhangjiang area is developing application scenario experience spaces to facilitate real-world interactions with robots, enhancing both training and public engagement [7] Group 3: Talent and Ecosystem Development - The "Future Point" community has been established in Zhangjiang to serve as a hub for top talent and innovation resources, focusing on disruptive innovation and talent discovery [9] - The community aims to create a four-dimensional innovation ecosystem that integrates talent, cognition, connection, and paradigms to support the needs of disruptive innovation [9] - Shanghai is committed to implementing the measures with a more open vision and practical actions to achieve world-leading future industry clusters by 2030 [9]

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][47]. Core Insights - The report highlights that the medical device procurement is gradually reflecting principles of "stabilizing clinical needs, ensuring quality, preventing collusion, and countering price wars" [6][30]. - The report suggests that the recent adjustments in procurement rules indicate a shift towards a more moderate approach, focusing on clinical needs and product quality rather than solely on low prices [6][30]. - The report emphasizes the potential for long-term development in the domestic medical device industry as procurement becomes more reasonable [6][30]. Summary by Sections Industry Overview - The closing index for the medical and biological sector is 8583.87, with a 52-week high of 9323.49 and a low of 6764.34 [2]. Market Performance - During the week of October 13-17, 2025, the A-share medical and biological sector fell by 2.48%, underperforming the CSI 300 index by 0.26 percentage points but outperforming the ChiNext index by 3.23 percentage points [7][36]. - The Hang Seng Healthcare Index decreased by 5.85%, underperforming the Hang Seng Index by 1.88 percentage points [7][36]. Industry Opinions and Investment Recommendations 1. **Innovative Drugs**: The innovative drug sector is experiencing adjustments, with a recommendation to maintain or increase positions based on long-term industry development logic. Key companies to watch include Innovent Biologics, 3SBio, and others [8][21]. 2. **Medical Devices**: The report notes that the National Medical Insurance Administration's recent procurement documents aim to optimize price differences and control "anchor points," indicating a move away from simply selecting the lowest bid [8][29]. 3. **Research Services**: The report expresses optimism about investment opportunities in the research services sector, particularly for companies with strong competitive advantages [26]. Sector Valuation - As of October 17, 2025, the overall valuation of the medical sector (TTM) is 30.03, a decrease of 0.84 from the previous week. The sector's valuation premium over the CSI 300 index is 123.96%, down by 4.90 percentage points [43].

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.48% from October 13 to October 17, underperforming the broader market index, the CSI 300, which fell by 2.22% [3][8] - There is a sustained enthusiasm for business development (BD) transactions in innovative drugs, with several companies entering agreements with international pharmaceutical firms [3][12] - The ESMO conference held from October 17 to 21 showcased positive advancements in multiple studies, particularly in immunotherapy and antibody-drug conjugates (ADCs), highlighting the potential of domestic biotech companies [3][11] Market Weekly Review - The pharmaceutical and biotechnology sector saw a weekly decline of 2.48%, with offline pharmacies and traditional Chinese medicine showing slight gains of 0.59% and 0.38%, respectively [8] - Medical research outsourcing, medical devices, and other biological products faced significant declines, with drops of 6.46%, 5.37%, and 3.6% respectively [8][9] - Notable stock performances included Asia-Pacific Pharmaceutical with a rise of 36.7%, while Betta Pharmaceuticals saw a decline of 17.0% [11] Industry News and Key Company Announcements Important Industry Events - On October 18, Kangfang Biologics presented data on a PD-1/VEGF dual antibody in non-small cell lung cancer at the ESMO conference, showing significant improvement in progression-free survival (PFS) [11] - On October 16, Hansa Biopharma announced a licensing agreement with Roche for the global exclusive rights to develop and commercialize HS-20110, with an upfront payment of $80 million [12] - On October 16, Prigen Biologics entered a collaboration with Gilead's Kite Pharma, receiving an upfront payment of $120 million [12][13] Company Announcements - Huayuan Biologics reported a slight decrease in total revenue for the third quarter, amounting to 936 million yuan, a 0.2% year-on-year decline [14] - Shanghai Pharmaceuticals received FDA approval for Doxycycline capsules, with projected sales of approximately $130 million in the U.S. for 2024 [14][16]

Market Performance - Major indices experienced a decline, with the Shanghai Composite Index falling by 1.95%, Shenzhen Component Index down by 3.04%, and ChiNext Index dropping by 3.36%, all breaking below the 30-day support line [1] - Hong Kong's Hang Seng Index decreased by 2.48%, and the Hang Seng Tech Index fell by 4.05%, both reaching a one-month low [1] - Weekly performance showed that except for the CSI Dividend Index which rose by 0.67%, all major indices in Hong Kong and A-shares were in the red, with the Hang Seng Tech Index down nearly 8% for the week [1][3] Sector Performance - In the Shenwan first-level industry sectors, banking and coal sectors saw the highest gains, while electronics, media, automotive, and telecommunications experienced significant pullbacks [5] - The banking sector rose by 4.89% and coal by 4.17%, while sectors like electronics and media saw declines of over 7% [7][8] ETF Performance - The A500 ETF (512050) fell by 3.17% this week, significantly lower than the over 5% drop in innovation indices [10][12] - The consumption ETF was the best performer this week, with a slight decline of 0.35%, recovering its year-to-date losses and turning positive by 3.18% [15] - The Hong Kong innovative drug ETF dropped nearly 6% this week, with a cumulative decline of 9.67% in October [22][24] Investment Opportunities - The A500 ETF is highlighted as an ideal tool for investing in core A-share assets, with a balanced coverage of 35 first-level industries and a focus on leading companies [12][14] - The index's structure includes a mix of traditional, cyclical, and technology growth sectors, providing a defensive investment strategy [13] - The upcoming Q4 is expected to present new consumption growth opportunities, particularly in service-oriented sectors, as well as potential rebounds in innovative drug and medical device sectors [21][22][24]